Inimmune has completed enrollment in its Phase 2 trial for INI-2004, an innovative treatment for allergic rhinitis, expected to yield crucial data soon.

This article explores a survey revealing that over half of those suffering from allergic rhinitis hesitate to seek treatment due to long wait times in hospitals, highlighting a need for improved access to care.

Inimmune Corporation has initiated its Phase 2 clinical trial to evaluate INI-2004 for allergic rhinitis, aiming to provide new lasting relief for patients.

Keymed's Stapokibart, an IL-4Rα monoclonal antibody, shows promising results in treating moderate-to-severe seasonal allergic rhinitis, as published in Nature Medicine.

A recent clinical trial demonstrates that SEBclausii™ effectively alleviates symptoms of acute allergic rhinitis, showcasing its safety and efficacy, and enhancing immune function.

Keymed Biosciences has announced the approval of its new drug Stapokibart, which targets seasonal allergic rhinitis, enhancing patient care in China.